NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 411
(Total Views: 41)
Posted On: 08/16/2024 3:52:55 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (‘GIP’), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound(R). The objective would be to evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much,” a recent article reads. “Lexaria’s latest study in an oral capsule hopes to evidence improved tolerability while also producing measurable quantities of drug in blood. This will be Lexaria’s first-ever work with the tirzepatide molecule and, as such, any noteworthy delivery of tirzepatide through oral delivery could be a significant finding,” said Chris Bunka, Lexaria’s CEO.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (‘GIP’), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound(R). The objective would be to evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much,” a recent article reads. “Lexaria’s latest study in an oral capsule hopes to evidence improved tolerability while also producing measurable quantities of drug in blood. This will be Lexaria’s first-ever work with the tirzepatide molecule and, as such, any noteworthy delivery of tirzepatide through oral delivery could be a significant finding,” said Chris Bunka, Lexaria’s CEO.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
